References
- Ahn MJ, Kim CY, Lee JS, Kim TG, Kim SH, Lee CK, Lee BB, Shin CG, Huh H, Kim J. 2002. Inhibition of HIV-1 integrase by galloyl glucoses from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med. 68:457–459.10.1055/s-2002-32070
- Ambika SPP, Chauhan SMS. 2014. Activity-guided isolation of antioxidants from the leaves of Terminalia arjuna. Nat Prod Res. 28:760–763.
- Bag A, Chattopadhyay RR. 2014. Efflux-pump inhibitory activity of a gallotannin from Terminalia chebula fruit against multidrug-resistant uropathogenic Escherichia coli. Nat Prod Res. 28:1280–1283.10.1080/14786419.2014.895729
- Beutler JA. 2009. Natural products as a foundation for drug discovery. Curr protoc pharmacol / editorial board, SJ Enna. 46:9.11.1–9.11.21.
- CDC. 1981. Pneumocystis pneumonia – Los Angeles. MMWR. 30:250–252.
- Harvey A. 2000. Strategies for discovering drugs from previously unexplored natural products. Drug Discovery Today. 5:294–300.10.1016/S1359-6446(00)01511-7
- Johnston R, Barré-Sinoussi F. 2012. Controversies in HIV cure research. J Int AIDS Soc. 15:16–23.10.1186/1758-2652-15-16
- Joshi SP, Kulkarni SS. 2013. Microbiocides from plant extract for protection against HSV 2 infection. U.S. patent Application No 14/398,313.
- Martino VS, López P, Martinez-Irujo JJ, Sanromán M, Cuevas MT, Santiago E, Lasarte JJ, Font M, Coussio JD, Monge A. 2002. Inhibitory effect against polymerase and ribonuclease activities of HIV-reverse transcriptase of the aqueous leaf extract of Terminalia triflora. Phytother Res. 16:778–780.10.1002/ptr.1065
- Martino V, Morales J, Martínez-Irujo JJ, Font M, Monge A, Coussio J. 2004. Two ellagitannins from the leaves of Terminalia triflora with inhibitory activity on HIV-1 reverse transcriptase. Phytother Res. 18:667–669.10.1002/ptr.1504
- Nadkarni A. K. 1996. Terminalia paniculata Roxb. In: Nadkarni AK, Nadkarni KM, editors. Indian materia medica. 3rd ed. Mumbai: Popular Prakashan; p.1121.
- Newman DJ, Cragg GM. 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 75:311–335.10.1021/np200906s
- Seal A, Aykkal R, Babu RO, Ghosh M. 2011. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation. 5:430–439.10.6026/bioinformation
- Stadeli KM, Richman DD. 2013. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antiviral Ther. 18:115–123.
- Talwar S, Nandakumar K, Nayak PG, Bansal P, Mudgal J, Mor V, Rao CM, Lobo R. 2011. Anti-inflammatory activity of Terminalia paniculata bark extract against acute and chronic inflammation in rats. J Ethnopharmacol. 134:323–328.10.1016/j.jep.2010.12.015
- Tshikalange TE, Meyer JJM, Lall N, Muñoz E, Sancho R, Van de Venter M, Oosthuizen V. 2008. In vitro anti-HIV-1 properties of ethnobotanically selected South African plants used in the treatment of sexually transmitted diseases. J Ethnopharmacol. 119:478–481.10.1016/j.jep.2008.08.027
- Valsaraj R, Pushpangadan P, Smitt UW, Adsersen A, Christensen SB, Sittie A, Nyman U, Nielsen C, Olsen CE. 1997. New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. J Nat Prod. 60:739–742.10.1021/np970010m
- Yu YB, Miyashiro H, Nakamura N, Hattori M, Park JC. 2007. Effects of triterpenoids and flavonoids isolated from Alnus firma on HIV-1 viral enzymes. Arch Pharmacal Res. 30:820–826.10.1007/BF02978831